Today's Pharma Pulse
Jazz Pharma’s Zepzelca misses survival goal in Phase III lung cancer trial
Jazz Pharmaceuticals reported that its lung‑cancer drug Zepzelca did not improve overall survival in the Phase III Lagoon trial for second‑line small‑cell lung cancer, jeopardizing its accelerated approval in this setting. The study of 724 patients showed median overall survival of 8.7 months with Zepzelca alone and 10.9 months with the combination, compared with 10.7 months for control.
Also developing:
By the numbers: Parabilis Medicines raises $2.4B in IPO
AWS Unveils Amazon Bio Discovery, Cutting Drug Design Time From Months to Weeks
Amazon Web Services launched Amazon Bio Discovery, an AI‑driven platform that lets researchers design and evaluate drug molecules without writing code. Early adopters such as Bayer, the Broad Institute and Memorial Sloan Kettering report that the tool can compress months‑long workflows into weeks, generating up to 300,000 antibody candidates in a single run.
GLP-1 Goes For The Middle
Indian pharmaceutical firms are rapidly converting the GLP‑1 hype into scale after Novo Nordisk’s semaglutide patent expired in March. Generics from Sun Pharma, Torrent, Zydus and others have already captured more than 15% of the market, pushing Novo’s share down...
NTU Singapore, SUSTech, and Lipigon Advance Inhaled Nanocarrier Therapy for Severe Lung Infections
Nanyang Technological University in Singapore, Southern University of Science and Technology in China, and Sweden’s Lipigon Pharmaceuticals have pushed their inhaled nanocarrier drug targeting ANGPTL4 into non‑human primate testing. The move clears the path toward an IND filing and could...
Helical Secures $10 Million Seed Round to Launch Virtual AI Lab for Pharma
Helical Ltd., a biotech AI startup, closed a $10 million seed round led by Redalpine Venture Partners, with participation from Gradient, BoxGroup, Frst Capital and several AI CEOs. The funding will accelerate deployment of its virtual AI lab that turns foundation...
AI Models Map Worm Brain, Scale to Synthetic Biology
The C. elegans nervous system has exactly 302 neurons and 7,000 synaptic connections. Scientists have had the full wiring diagram since 1986. What they haven't had: a computational model that captures how those neurons actually develop and wire themselves up. Eric Wasiolek...
Patent‑Free COVID Vaccine Reaches 100 Million at $2‑3
Except the opposite, I make low cost vaccines that actually bypass big pharma, our patent-free COVID vaccine reached 100 million people at $2-3 per dose. It’s sad to see so many give up their critical thinking skills for conspiracy sites,...
Traws Pharma Inc (TRAW) Q4 2025 Earnings Call Transcript
Harrow Health reported Q4 2025 revenue of $89.1 million, a 33% year‑over‑year increase, and full‑year revenue of $272 million, up 36%. Management forecast 2026 revenue between $350 million and $365 million, with adjusted EBITDA of $80‑100 million, driven by sales‑force...
Consumers, Employers Make Joint Call For Price Transparency Reform
A coalition of consumer advocates, employers and health‑payer groups is urging Congress to pass a price‑transparency law that would require providers to disclose the true cost of treatments and prescription drugs at the point of care. The proposal also calls...
Sonodynamic Therapy with Ferrocene-Modified Frameworks Targets Breast Cancer Metastasis
Researchers at Beijing Institute of Technology have engineered ferrocene‑modified covalent organic frameworks (mCOFs) that act as ultrasound‑activated sonosensitizers. When combined with sonodynamic therapy, the nanoplatform reduces breast cancer cell viability to 24.3% and drives apoptosis above 84%, while simultaneously generating...
Psoriasis Paves the Way for Next-Generation TYK2 Inhibitors in Autoimmunity
Takeda and Alumis reported Phase III data for their next‑generation TYK2 inhibitors, zasocitinib and envudeucitinib, showing more than half of patients achieve PASI 90 in plaque psoriasis. The results close the efficacy gap between oral agents and injectable biologics, surpassing the 28%...
EU Launches PsyPal Project to Test Psychedelic Therapy for Palliative Care Distress
The European Union has inaugurated the PsyPal project, a research initiative that will evaluate psychedelic therapy for patients experiencing psychological distress in palliative care. The launch event took place on 13 April 2026 at the Directorate‑General for Health and Food Safety, signaling...
Seattle Children’s Hospital Cuts Infant Leukemia Diagnosis to One Day
Seattle Children’s Hospital’s Sarthy Lab has begun delivering infant acute lymphoblastic leukemia diagnostic results in a single day using Benchling’s AI platform. The breakthrough, highlighted by Mallory Carlson’s twins, promises faster treatment decisions and less anxiety for families.
Phospholipid Asymmetry Helps Explain Extracellular Vesicle Surface Charge and Therapeutic Quality
Researchers led by Naohiro Seo and Takanori Ichiki published a review in ACS Nano Medicine that links extracellular vesicle (EV) surface charge to phospholipid asymmetry, especially the distribution of phosphatidylserine (PS). They show exosomes retain PS on the inner leaflet,...
CAR T Cell Therapy Biomanufactured by Cellares Infused Into First Two Patients
Cellares has successfully infused the first two patients with rese‑cel, Cabaletta Bio’s investigational autologous CAR‑T therapy, using its automated Cell Shuttle manufacturing platform. The product met all GMP release criteria, demonstrating that a low‑cost, high‑capacity process can produce clinical‑grade cell...
When Political Speech Becomes a Clinical Exposure
The letter highlights chronic underfunding of women’s health research and warns that high‑profile political statements can act as a clinical exposure, rapidly altering prescribing patterns. Data from the United States show a 10% drop in acetaminophen orders for pregnant women...
Adcendo Raises $75M to Advance Cancer Drug Pipeline
Adcendo, a Copenhagen‑Boston biotech focused on antibody‑drug conjugates (ADCs), announced a $75 million Series C financing led by Jeito Capital. The capital will accelerate Phase 1 trials for three lead ADC candidates targeting tissue factor, uPARAP, and a preclinical asset. The round attracted...
Stanford Team Demonstrates Ultrasound‑Powered Nanophosphor Light Source Inside Living Tissue
Stanford scientists have shown that mechanoluminescent nanophosphors injected into the bloodstream can emit blue light when triggered by external ultrasound, creating a controllable, deep‑tissue light source in live mice. The breakthrough could replace invasive fiber optics for neuromodulation, gene editing...
FDA Grants First Gene‑Therapy Approval for Rare Pediatric Immune Disorder LAD‑I
The U.S. FDA has approved Rocket Pharmaceuticals’ Kresladi (marnetegragene autotemcel) for children with leukocyte adhesion deficiency type I, marking the world’s first gene‑therapy option for the disease. Approval follows a single‑arm trial of nine patients that showed 100% survival and restored...
CDER SBIA Chronicles
The FDA’s CDER Small Business & Industry Assistance (SBIA) Chronicles newsletter delivers regulatory guidance to drug manufacturers through a series of podcasts and a searchable archive. The most recent episodes—released on Dec 13 2024, Nov 14 2024, and May 17 2024—cover centralized statistical monitoring for data...
Pharmacy's Rising Role in Cell and Gene Therapy: Zahra Mamoudjafari, PharmD, MBA
Cell and gene therapies (CGTs) are receiving approvals faster than health‑care institutions can operationalize them. Zahra Mahmoudjafari, a clinical pharmacy leader at the University of Kansas Health System, published a framework outlining eight interdependent domains needed for financially sustainable, patient‑accessible...
Helpful Webinars and Other Resources for Generic Drug Manufacturers
The FDA has compiled a suite of webinars, workshops and seminars aimed at helping generic drug manufacturers improve their abbreviated new drug application (ANDA) submissions. Topics span bioequivalence studies, inactive ingredient databases, sample retention, and product‑specific challenges for oral, inhalation,...
Hims & Hers Health, Inc. Dba Hers - 716825 - 09/09/2025
The FDA issued a warning letter to Hims & Hers Health, Inc., alleging that the company’s website falsely marketed its compounded semaglutide as equivalent to FDA‑approved products like Ozempic and Wegovy. The agency cites violations of FDCA sections 502(a), 502(bb)...
About the Quantitative Medicine Center of Excellence (QM CoE)
The FDA’s Center for Drug Evaluation and Research (CDER) has launched the Quantitative Medicine Center of Excellence (QM CoE) to centralize quantitative expertise across its offices. Governance includes senior leaders from the Offices of Generic Drugs, New Drugs, Pharmaceutical Quality,...
Cancer Dependency Map Consortium Launches Phase 3 to Accelerate Next-Generation Therapeutics
The Broad Institute’s Cancer Dependency Map Consortium (DMC) has entered Phase 3, expanding its mission beyond cataloguing tumor vulnerabilities to tackling drug resistance, surface‑protein targets, and high‑dimensional readouts. Backed by 23 pharma partners, the consortium builds on DMC 2.0’s expansion to over...
Elahere Combination Achieves 62.7% ORR in Phase 2 Trial for Platinum-Sensitive Ovarian Cancer at SGO 2026
AbbVie’s Elahere (mirvetuximab soravtansine) combined with carboplatin produced a confirmed objective response rate of 62.7% in patients with FRα‑positive, platinum‑sensitive ovarian cancer, meeting the primary endpoint of the Phase 2 IMGN853‑0420 trial presented at SGO 2026. The study enrolled 125 participants,...
Physics‑Based Sensors and AI Transform Bioreactor Monitoring
Bioreactors are billion-dollar processes monitored by pH probes and dissolved oxygen sensors. That's like running a semiconductor fab with a thermometer. @schmidtsciences is adapting physics tools that don't usually touch biology: fluorescent nanodiamonds, single-cell Raman spectroscopy, and optical frequency combs that...
GLP-1 Drug Improves Liver Health Independent of Weight Loss, Mouse Study Finds
Researchers at Toronto’s Sinai Health discovered that semaglutide, a GLP‑1 agonist, improves liver function by acting directly on liver sinusoidal endothelial cells, independent of weight loss. The study, published in Cell Metabolism, used mouse models of metabolic dysfunction‑associated steatohepatitis (MASH)...
Targeting Aging: Epigenetic Reprogramming Tackles Disease Root
Aging is arguably the root cause of most major diseases. Our cells lose function as we age, allowing various conditions to manifest, which is why most major diseases correlate with age. Yes, it is more complex than this, but this is...
Low‑cost Vaccines Bypass Big Pharma, Influencers Profit
No, the opposite. I develop low cost vaccines that bypass big pharma. The only shills are those connected to the corrupt wellness influencer industry, which buys whatever it can in bulk cheap so they can jack up the price with...
Pharmaceutical Executive Daily: AbbVie and Haisco Enter $745 Million Licensing Agreement
AbbVie signed an exclusive licensing deal with China’s Haisco Pharmaceutical to develop, manufacture and sell a suite of novel pain compounds outside mainland China, Hong Kong and Macau. The agreement provides Haisco $30 million upfront and up to $715 million in milestone payments,...
FDA Bolsters Bespoke Therapy Framework with New Draft Safety Guidelines
The FDA’s Center for Biologics Evaluation and Research issued draft guidance to standardize safety assessments for genome‑editing therapies, covering both ex vivo and in vivo products that use next‑generation sequencing to detect off‑target effects. The recommendations target nonclinical studies supporting IND and...
Nasal EV Spray Reverses Neuroinflammation and Boosts Memory
A nasal spray delivering extracellular vesicles reversed neuroinflammation, restored mitochondrial function, and improved memory in aging brain models, suggesting a noninvasive approach to counteract cognitive decline. neuroscience
Grapefruit Compound Bergamottin Blocks STAT3, Triggers Tumor Cell Death
Bergamottin, a natural furanocoumarin obtained from grapefruit juice induces chemosensitization and apoptosis through the inhibition of STAT3 signaling pathway in tumor cells https://t.co/cLRxHMFBCJ
Fordham 33 (Report 4): Life Sciences and Healthcare Innovation
A multinational panel at Fordham’s IPKat event dissected life‑science patent strategies across the U.S., Europe, Japan and the upcoming Unified Patent Court. Speakers highlighted how European protocol disclosures reveal methods but not results, making anticipatory rejections rare, while U.S. product‑for‑use...
One Injection Restores Hearing via OTOF Gene Therapy
A single injection uses an engineered AAV virus to deliver a healthy OTOF gene into cochlear cells, enabling them to produce otoferlin and restore the ear’s ability to convert sound vibrations into signals the brain can interpret. https://t.co/Lk34jpnRBe
FDA's 27-Year Freeze Stalled Critical Strep A Vaccine
The FDA accidentally froze Strep A vaccine development for 27 years. @AsimovPress explains what happened and where things stand now, ft. @jacobtrefethen and @coeff_giving's research.
Reproxalap Safe for Use in Patients With Dry Eye Disease
A Phase 3 trial of 0.25 % reproxalap eye drops in 757 dry‑eye disease patients found no serious treatment‑related adverse events. Mild ocular irritation was the most common side effect, occurring more often in older women. Visual acuity showed modest improvement, especially...
REPL CEO Skips
$REPL CEO tells me they’re not going to appeal the 2nd CRL but will try to work with FDA - for now, commercial team/other layoffs, cash runway til Q1 of next year, stock price -75% from Fri https://t.co/FLAiOcAAQB
AWS Launches Amazon Bio Discovery for AI-Powered Scientific Experimentation
Amazon Web Services unveiled Amazon Bio Discovery, a cloud‑based platform that supplies scientists with a curated library of biological foundation models (bioFMs) for generating and evaluating drug molecules. The service lets researchers train custom models on their own experimental data...
Updated: FDA Asks for Data on Lilly’s Foundayo to Assess Heart, Liver Risks
The U.S. Food and Drug Administration has asked Eli Lilly for additional safety data on its newly approved obesity medication, Foundayo. The agency is specifically seeking information on any cardiovascular events and liver‑related adverse effects observed in clinical trials and post‑marketing...
Replimune Looks Ahead as Repeat CRL Speeds the Company's Decline
Replimune received a second complete response letter (CRL) from the FDA for its lead oncolytic cancer therapy, citing additional data gaps and manufacturing concerns. The regulatory setback triggered a wave of layoffs affecting roughly 30% of its workforce and pushed...
Max Hodak’s Science Corp. Is Preparing to Place Its First Sensor in a Human Brain
Science Corp, the neurotechnology startup founded by former Neuralink president Max Hodak, has recruited Yale neurobiologist Murat Günel as a scientific adviser to oversee its first U.S. human trials of a bio‑hybrid brain‑computer interface. The company recently closed a $230 million Series C...
NEW STUDY: Frog-Derived Gut Bacterium Completely Eradicates 100% of Tumors After a Single Dose in Mice
A peer‑reviewed study in *Gut Microbes* reports that a single intravenous dose of the frog‑derived gut bacterium Ewingella americana eradicated colorectal tumors in 100% of immunocompetent mice. The live microbe outperformed both doxorubicin chemotherapy and anti‑PD‑L1 checkpoint blockade, achieving complete...
Neuralink Shifts to Speech‑Focused Brain‑Computer Interface Trials, Raising Viability Questions
Neuralink announced new speech‑restoration clinical trials at the University of Texas Southwestern Medical Center and Cleveland Clinic Abu Dhabi, moving away from its long‑standing motor‑cursor interface. The pivot follows criticism that its original brain‑computer interface (BCI) strategy lags behind competitors...
GLP‑1 Drugs Show Weight‑loss‑independent Benefits, Study Finds
Great work by @DanielJDrucker and team; biologically plausible mechanism of GLP1-RA benefit independent of weight loss. Excellent article by @megtirrell @CNN describing the publication. Could it justify new approaches for these drugs? I think so. https://t.co/pHudk7lkAR
FDA Grants Full Approval to Travere’s FILSPARI for FSGS, Unlocking $2B Market
Travere Therapeutics announced that the FDA has granted full approval to FILSPARI (sparsentan) for focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. The decision makes FILSPARI the first approved therapy for the rare kidney disease and expands the drug’s addressable U.S....
In the Clinic for April 14, 2026
The "In the clinic for April 14, 2026" page serves as a centralized hub that aggregates the latest Bioworld data snapshots, special reports, and infographics across biopharma, medical technology, and emerging therapeutic areas. It links to analyses on mRNA vaccine...
New CellCelector CLD Takes You From Thousands of Candidates to the Top Clone, Faster
German biotech equipment maker Sartorius has launched the CellCelector CLD, an automated imaging and cell isolation platform that accelerates monoclonal cell line development. The system combines high‑speed scanning, advanced imaging and gentle clone retrieval to screen up to 885 nanowell...
Gaps in Persistence, Coverage Limit GLP-1 Impact in Obesity
Two AMCP 2026 posters highlighted persistent gaps in GLP‑1 therapy for obesity. A claims‑based analysis of 53,183 patients showed persistence falling from 65% at 120 days to 34% at one year, with higher out‑of‑pocket costs and fewer clinician visits driving...
Novo Partners OpenAI as Ideaya's Eye Data Disappoints
Novo teams with OpenAI; Ideaya gets muted response to eye drug data https://t.co/U6sDZlMxyQ $NVO $IDYA $REGN $GSK